CARDURA XL Rx
Generic Name and Formulations:
Doxazosin (as mesylate) 4mg, 8mg; ext-rel tabs.
Indications for CARDURA XL:
Swallow whole. Take w. breakfast. Initially 4mg once daily; may titrate after 3–4 weeks to max 8mg/day. If therapy is stopped for several days, restart at 4mg once daily. Switching from Cardura to Cardura XL: initially 4mg once daily; do not take final evening dose of Cardura. Concomitant PDE-5 inhibitors: initiate at lowest dose.
Severe hepatic impairment: not recommended. Mild or moderate hepatic impairment. Syncope. Symptomatic hypotension. Exclude prostate cancer. Severe GI narrowing. Coronary insufficiency; discontinue if angina pectoris appears or worsen. Cataract surgery (intraoperative floppy iris syndrome possible). Elderly. Pregnancy, nursing mothers: not indicated for females.
Caution with strong CYP3A4 inhibitors (eg, atanazavir, clarithromycin, indinavir, ketoconazole, itraconazole, nefazodone, others). Additive hypotension with concomitant PDE-5 inhibitors.
Headache, dizziness, asthenia, hypotension, dyspnea, postural hypotension, somnolence, respiratory or urinary tract infections; rare: priapism.
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies